3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia
| Autor: | Sanders, Donald B, Juel, Vern C, Harati, Yadollah, Smith, A Gordon, Peltier, Amanda C, Marburger, Tessa, Lou, Jau-Shin, Pascuzzi, Robert M, Richman, David P, Xie, Tai, Demmel, Valentin, Jacobus, Laura R, Aleš, Kathy L, Jacobus, David P, Dapper Study Team |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male timed up-and-go Lambert-Eaton myasthenic syndrome efficacy Clinical Trials and Supportive Activities ELS Dapper Study Team Lambert-Eaton myasthenia Medical and Health Sciences Maintenance Chemotherapy Young Adult Deprescriptions Double-Blind Method Clinical Research 80 and over Humans LEMS Aged Lambert-Eaton syndrome Muscle Weakness Neurology & Neurosurgery Evaluation of treatments and therapeutic interventions clinical trial Middle Aged Neuromuscular Agents 4-diaminopyridine Eaton-Lambert syndrome LES 6.1 Pharmaceuticals Female amifampridine |
| Zdroj: | Muscle & nerve, vol 57, iss 4 |
| Popis: | INTRODUCTION:3,4-diaminopyridine has been used to treat Lambert-Eaton myasthenia (LEM) for 30 years despite the lack of conclusive evidence of efficacy. METHODS:We conducted a randomized double-blind placebo-controlled withdrawal study in patients with LEM who had been on stable regimens of 3,4-diaminopyridine base (3,4-DAP) for ≥ 3 months. The primary efficacy endpoint was >30% deterioration in triple timed up-and-go (3TUG) times during tapered drug withdrawal. The secondary endpoint was self-assessment of LEM-related weakness (W-SAS). RESULTS:Thirty-two participants were randomized to continuous 3,4-DAP or placebo groups. None of the 14 participants who received continuous 3,4-DAP had > 30% deterioration in 3TUG time versus 72% of the 18 who tapered to placebo (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|